New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform

ctDNA monitoring with Signatera: An overview for transplant providers

Tiny Traces, Big Impact: Changing the Paradigm in Breast Cancer Management with MRD Testing

Optimizing Patient Care in MIBC with MRD Testing, Real-world Clinical Cases

New Data Review Can treating molecular residual disease (MRD) in colorectal cancer improve outcomes

MRD Testing in NSCLC to Personalize Patient Care

Unlocking new uses for old drugs

a revolution in precision oncology using evidence-based MRD testing

New data: Optimizing breast cancer care and drug development with molecular residual disease testing

The Tipping Point: How clinically validated MRD testing is transforming patient management in colorectal cancer

Post ESMO review - How molecular residual disease testing is transforming cancer care

ASCO24 Summary: Latest data on ctDNA as a patient selection and early efficacy marker in drug development

Latest data on ctDNA as a patient selection and early efficacy marker for gynecologic cancers

How ctDNA can transform interventional trial design for GI cancers

Seeing the Forest Through the Trees: How tumor informed MRD testing can illuminate the treatment pathway in GI cancer

Review recently presented MRD data in colorectal and pancreatic cancer, exploring the potential impact on patient care

Webinar: Breast Cancer 2023 Data & Post-SABCS Summary

ctDNA in drug development for breast cancer Multiple studies have demonstrated that detection of molecular residual disease (MRD) is associated with poor prognosis in breast cancer. Ongoing prospectiv

Panel Discussion: How ctDNA Testing is Informing the Management of Patients With GI Cancer - Direct

Our experts will review real-world case studies showing when and where ctDNA can help inform shared decision-making.

Locate and Track: ctDNA Monitoring in NSCLC with Signatera

Learn about the clinical applications for Signatera in NSCLC across early stage and metastatic disease

ctDNA monitoring to optimize immunotherapy treatment decisions

Dive into the latest data highlighting ctDNA for immunotherapy treatment response monitoring

Detect. Monitor. Optimize: Signatera’s Impact on Breast Cancer Management

Learn more about the latest Signatera™ data in high-risk breast cancer: Newly published data from the I-SPY 2 trial reinforcing the utility of ctDNA monitoring during neoadjuvant therapy Updates from